

# Lauren Carter

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7103310/lauren-carter-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39  
papers

2,290  
citations

16  
h-index

47  
g-index

47  
ext. papers

3,839  
ext. citations

26.4  
avg, IF

4.9  
L-index

#	Paper	IF	Citations
39	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. <i>Science Immunology</i> , <b>2022</b> , 7,	28	3
38	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabn1252	17.5	3
37	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , eabl85063.3	33.3	65
36	De novo protein design by deep network hallucination. <i>Nature</i> , <b>2021</b> ,	50.4	33
35	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
34	F-domain valency determines outcome of signaling through the angiotensin pathway. <i>EMBO Reports</i> , <b>2021</b> , 22, e53471	6.5	4
33	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice <b>2021</b> ,		1
32	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines <b>2021</b> ,		12
31	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , <b>2021</b> , 592, 623-628	50.4	40
30	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters <b>2021</b> ,		10
29	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , <b>2021</b> , 594, 253-258	50.4	92
28	Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system <b>2021</b> ,		1
27	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples <b>2021</b> ,		1
26	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. <i>Cell</i> , <b>2021</b> , 184, 169-183. e172	56.2	327
25	Incorporation of sensing modalities into de novo designed fluorescence-activating proteins. <i>Nature Communications</i> , <b>2021</b> , 12, 856	17.4	7
24	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. <i>Scientific Reports</i> , <b>2021</b> , 11, 4290	4.9	9
23	Computational design of a synthetic PD-1 agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	9

22	SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. <i>Cell Chemical Biology</i> , <b>2021</b> ,	8.2	4
21	Multivalent designed proteins protect against SARS-CoV-2 variants of concern <b>2021</b> ,		4
20	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 1151-1161.e5	23.4	11
19	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. <i>Journal of Immunological Methods</i> , <b>2021</b> , 499, 113160	2.5	2
18	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16	56.2	34
17	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	13
16	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.. <i>Science Immunology</i> , <b>2021</b> , eabl5652	28	2
15	Characterizing protein G B1 orientation and its effect on immunoglobulin G antibody binding using XPS, ToF-SIMS, and quartz crystal microbalance with dissipation monitoring. <i>Biointerphases</i> , <b>2020</b> , 15, 021002	1.8	6
14	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 <b>2020</b> ,		7
13	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 <b>2020</b> ,		10
12	F-domain valency determines outcome of signaling through the angiotensin pathway <b>2020</b> ,		28
11	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , <b>2020</b> , 183, 1367-1382.e17	56.2	217
10	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , <b>2020</b> , 370, 426-431	33.3	219
9	Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy. <i>Scientific Reports</i> , <b>2019</b> , 9, 6169	4.9	6
8	Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. <i>Cell</i> , <b>2019</b> , 176, 1420-1431.e17	56.2	190
7	De novo design of potent and selective mimics of IL-2 and IL-15. <i>Nature</i> , <b>2019</b> , 565, 186-191	50.4	184
6	De novo design of a non-local $\beta$ -sheet protein with high stability and accuracy. <i>Nature Structural and Molecular Biology</i> , <b>2018</b> , 25, 1028-1034	17.6	54
5	De novo design of a fluorescence-activating $\beta$ -barrel. <i>Nature</i> , <b>2018</b> , 561, 485-491	50.4	156

4	Massively parallel de novo protein design for targeted therapeutics. <i>Nature</i> , <b>2017</b> , 550, 74-79	50.4	235
3	Global analysis of protein folding using massively parallel design, synthesis, and testing. <i>Science</i> , <b>2017</b> , 357, 168-175	33.3	241
2	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005409	7.6	36
1	Sampling of Structure and Sequence Space of Small Protein Folds		4